含有抗微生物的可生物降解纳米乳液,用于有效清除细菌外周炎中的细胞内病原体
Jessa Marie V Makabenta1, Ahmed Nabawy1, Aritra Nath Chattopadhyay1
1Department of Chemistry, University of Massachusetts Amherst, 710 North Pleasant Street, Amherst, MA, 01003, United States.
Biomaterials
|October 19, 2023
概括
这项研究引入了含有欧原醇的可生物降解纳米乳液 (BNEs),用于对抗细胞内感染,提供一种非抗生素方法. 电子BNE有效清除细菌,并显示出对抗炎等多药耐药性感染的前景.
科学领域:
- 纳米医学是一种纳米医学.
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
背景情况:
- 细胞内细菌由于宿主细胞的入侵和多药性耐药性 (MDR) 造成了治疗挑战.
- 标准抗生素通常对细胞内病原体无效,需要新的治疗策略.
研究的目的:
- 开发和评估一种非抗生素策略,使用带有植物化学物质的可生物降解纳米乳液 (BNEs) 治疗细胞内细菌感染.
- 评估带有优素醇的BNE (E-BNE) 对细胞内细菌,特别是对甲基西林耐药黄金葡萄球菌 (MRSA) 的疗效.
主要方法:
- 用抗微生物植物化学品装载的聚合物稳定生物降解纳米乳液 (BNEs) 的制造.
- 评估E-BNEs的抗菌疗效,巨细胞向,生物相容性和细胞进入机制 (胆固醇依赖的膜融合).
- 在MRSA诱导腹膜炎的小鼠模型中评估E-BNEs,并评估耐药性选择.
主要成果:
- 带有尤金醇的BNE (E-BNE) 显示出优异的抗菌活性,巨细胞积累和生物相容性.
- 通过胆固醇依赖的膜融合,E-BNEs促进了欧原醇进入巨细胞,有效地杀死细胞内MRSA.
- 在腹膜炎模型中,E-BNE逆转了MRSA诱导的免疫抑制,没有诱导耐药性,并实现了99%的细菌清除,表现优于vancomycin.
结论:
- 可生物降解的纳米乳液提供了一个有希望的非抗生素平台,用于提供抗菌植物化学物质来治疗细胞内感染.
- 电子BNE代表了对抗MDR细胞内病原体的有效策略,并显示出对周周炎和其他耐火性感染的显著治疗潜力.
相关概念视频
Surface Membrane Barriers
1.1K
The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
1.1K
Biological Methods for Microbial Control
42
Biological agents offer an effective means of controlling microbial growth by leveraging natural processes like predation, competition, and the secretion of antimicrobial substances.Predatory bacteria such as Bdellovibrio species target and kill pathogens like Salmonella and E. coli. They are widely used in poultry farms to control infections. Myxococcus species help combat plant-pathogenic fungi. These naturally occurring predators serve as eco-friendly alternatives to chemical pesticides and...
42
Antimicrobial Proteins
1.0K
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
1.0K
Antimicrobial Effectiveness
24
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
24
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
26
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
26


